NCT06260410
Recruiting
Not Applicable
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
ConditionsProstate Cancer Metastatic
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer Metastatic
- Sponsor
- Erasmus Medical Center
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Overall survival
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Investigators
S. L. W. (Stijn) Koolen
Assistant Professor, Hospital Pharmacist, Clinical Pharmacologist
Erasmus Medical Center
Eligibility Criteria
Inclusion Criteria
- •Participants should be at least 18 years old.
- •Participants should be able to understand the written information and be able to provide informed consent.
- •Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.
Exclusion Criteria
- •None applicable
Outcomes
Primary Outcomes
Overall survival
Time Frame: 44 months
Overall survival will be defined as the time from inclusion to death from any cause.
Secondary Outcomes
- Progression free survival(44 months)
- Heterogeneity of PSMA-positivity(44 months)
- Effect of CTC PSMA expression on response to treatment.(44 months)
- PSMA-PET scan data and response to treatment.(44 months)
- Effect of biomarkers in blood on response to treatment.(44 months)
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Data collection in Lutetium Treated Prostate cancer: Recording of Progression and Tumor Characteristicsmetastatic castration-resistant prostate cancerProstate cancer10038597NL-OMON56531Erasmus MC, Universitair Medisch Centrum Rotterdam150
Completed
Not Applicable
Validation of the Stockholm3 Test for Detection of Prostate Cancer in the Swiss PopulationProstate CancerLocalized CarcinomaNCT05294627University Hospital, Basel, Switzerland380
Completed
Not Applicable
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsProstate CancerNCT02376296Saladax Biomedical, Inc.35
Completed
Not Applicable
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate BiopsyProstate CancerNCT00373035Wake Forest University Health Sciences60
Withdrawn
Not Applicable
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation ToxicityProstate CancerNCT04580667DiaCarta, Inc.250